Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Abstract A1-09: Functional analysis of the chr13q22.1 pancreatic cancer risk locus suggests allele-specific effects on DIS3 expression with prognostic implications
Ibrahim, Abdisamad , Emmanuel, Mickey , Manmiller, Sarah, Jia, Jinping , Collins, Irene , Ylaya, Kris , Altekruse, Sean F. , Petersen, Gloria M. , Ámundadóttir, Laufey T. , Hoskins, Jason W. , Jia, Jinping, Parikh, Hemang M. , Hewitt, Stephen M. , Amundadottir, Laufey

Mayo Clinic

Cancer Research | November 20, 2015 | Volume: 75 | Issue: 22_Supplement_1 | Pages: A1-09-A1-09

10.1158/1538-7445.transcagen-a1-09 Get It

Abstract A genome-wide association study (GWAS) of pancreatic cancer conducted within the NCI Cohort Consortium (PanScan I and II) identified pancreatic cancer susceptibility loci on chromosomes 1q32.1/NR5A2, 5p15.33/CLPTM1L/TERT, 9q34.2/ABO, and 13q22.1. The most significant single-nucleotide polymorphism (SNP) identified on 13q22.1, rs9543325, lies in a ~600 kb gene desert; the nearest genes are KLF5, KLF12, PIBF1, DIS3, and BORA (265–586 kb away). Imputation using the 1000 Genomes and DCEG reference datasets did not improve the GWAS signal, but produced a set of highly correlated SNPs for functional follow-up. We performed eQTL analysis to test for association between the genotypes of these functional candidate variants and expression of nearby genes. Among 64 normal derived pancreatic tissue samples, DIS3 expression showed the strongest association with a 30 bp indel variant in the risk locus (P = 4.8 × 10-4), indicating risk alleles associate with reduced DIS3 expression. Mutations in DIS3 have previously been identified in acute myeloid leukemia and multiple myeloma, and its expression has been correlated with metastatic potential in colorectal cancer, suggesting DIS3 is relevant to cancer biology. Chromosome conformation capture identified a physical interaction between the indel-containing locus and a region near the DIS3 promoter. Luciferase assay for regulatory function of this indel-containing locus revealed allele-specific silencer activity for the insertion allele. Supershift electromobility shift assay (EMSA) demonstrated binding of LEF1 specifically to the insertion allele of the indel, which contains two in silico predicted LEF1 binding elements. Finally, through immunohistochemical analysis, high DIS3 protein levels associated with better survival for pancreatic cancer patients (hazard ratio = 2.87, 95% CI = 1.49–5.53, P = 0.001). Our results suggest that at least one target gene for the pancreatic cancer risk variants on chr13q22.1 may be DIS3, and that the underlying biology may be mediated by the novel indel through a long-range repressive effect on DIS3 expression. Citation Format: Jason W. Hoskins, Abdisamad Ibrahim, Mickey Emmanuel, Sarah Manmiller, Jinping Jia, Hemang Parikh, Irene Collins, Kris Ylaya, Sean F. Altekruse, Stephen M. Hewitt, Gloria M. Petersen, Laufey T. Amundadottir. Functional analysis of the chr13q22.1 pancreatic cancer risk locus suggests allele-specific effects on DIS3 expression with prognostic implications. [abstract]. In: Proceedings of the AACR Special Conference on Translation of the Cancer Genome; Feb 7-9, 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 1):Abstract nr A1-09.
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)
Investigators, The Huntington Study Group PHAROS, Biglan, Kevin , Shoulson, Ira , Kieburtz, Karl , Oakes, David , Kayson, Elise, Shinaman, M. Aileen, Zhao, Hongwei , Romer, Megan, Young, Anne B., Hersch, Steven M. , Penney, Jack, Marder, Karen, Paulsen, Jane S. , Quaid, Kimberly A., Siemers, Eric , Mallonee, William, Suter, Greg, Dubinsky, Richard , Nance, Martha , Bundlie, Scott R., Radtke, Dawn, Kostyk, Sandra K. , Baic, Corrine, Walker, Francis O. , Hunt, Victoria, Chouinard, Sylvain, Wood‐Siverio, Cathy, Corey‐Bloom, Jody , Peavy, Guerry M. , Moskowitz, Carol, Wesson, Melissa, Samii, Ali, Bird, Thomas D. , Lipe, Hillary, Blindauer, Karen, Marshall, Frederick J., Zimmerman, Carol, Goldstein, Jody, Rosas, Diana, Novák, Péter , Caviness, John N., Duffy, Amy, Wheelock, Vicki, Tempkin, Teresa, Seeberger, Lauren , Albin, Roger L. , Racette, Brad A. , Perlman, Susan , Bordelon, Yvette , Martin, W. R. Wayne , Wieler, Marguerite , Raymond, Lynn A. , Decolongon, Joji, Hunter, Christine , Hauser, Robert A. , Furtado, Sarah , Suchowersky, Oksana , Klimek, Mary Lou, Guttman, Mark, Sethna, Rustom, Feigin, Andrew, Cox, Marie, Shannon, Barbara , Percy, Alan K. , Dure, Leon , Harrison, Madaline B. , Higgins, Donald S. , Molho, Eric , Nickerson, Constance, Evans, Sharon, Hobson, Douglas, Singer, Carlos , Gálvez-Jiménez, Néstor, Shannon, Kathleen M. , Comella, Cynthia , Ross, Christopher A. , Hogarth, Penelope , Weiner, William J., Como, Peter G., Kumar, Rajeev , Cotto, Candace, Stout, Julie C. , Brocht, Alicia, Watts, Arthur, Eberly, Shirley , Weaver, Christine , Gusella, James F. , MacDonald, Marcy E., Fahn, Stanley, Shults, Clifford W., Caviness, John, Investigators, The Huntington Study Group PHAROS, Tanner, Caroline M. , Gray, Carolyn Steele , Baic, Corrine L., Caress, James B. , O’Neill, Christine J. , Factor, Stewart Alan , Greenamyre, J. Timothy , Song, David , Adler, Charles H. , Richman, David P. , Chou, Kelvin L. , Perlmutter, Joel S. , Leavitt, Blair R. , Clarke, Lorne A. , Jankovic, Joseph J. , Sanchez‐Ramos, Juan , Johnson, William , Saint‐Hilaire, Marie , Testa, Claudia M. , Rosenblatt, Adam E , Foroud, Tatiana , Myers, Richard H. , Ross, Christopher A , Hauser, Robert A

Mayo Clinic

JAMA Neurology | November 16, 2015 | Volume: 73 | Issue: 1 | Pages: 102

10.1001/jamaneurol.2015.2736 | PMID 26569098 Get It

Endoscopic ultrasound-guided fine-needle aspiration of a pulmonary artery malignant thrombus
Gincul, Rodica , Gómez, Victoria , Kerr, Sarah E. , Levy, Michael J. , Zhang, Jun , Levy, Michael J.

Mayo Clinic

Endoscopy | November 5, 2015 | Volume: 47 | Issue: S 01 | Pages: E547-E549

10.1055/s-0034-1393319 | PMID 26540306 Get It

Transbronchial Cryobiopsies in the Evaluation of Lung Allografts: Do the Benefits Outweigh the Risks?
Roden, Anja C. , Kern, Ryan , Aubry, Marie Christine, Jenkins, Sarah M. , Yi, Eunhee S. , Maldonado, Fabien , Scott, John P., Kern, R

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 21, 2015 | Volume: 140 | Issue: 4 | Pages: 303-311

10.5858/arpa.2015-0294-oa | PMID 26488148 Get It

Transbronchial cryobiopsy technique yields larger biopsies with enhanced quality. The benefits and safety of cryobiopsies have not been thoroughly studied in lung allografts.Context.— To compare size, quality, reproducibility of interpretation of rejection and complications of cryobiopsies with those of conventional biopsies from lung allografts.Objective.— All cryobiopsies (March 2014–January 2015) of lung allografts performed at Mayo Clinic, Rochester, and medical records were reviewed. For comparison, conventional biopsies from the same patient or, if unavailable, from a random patient, were selected. Two pathologists blinded to outcome reviewed all biopsies. Specimen volume, number of alveoli, small airways, and pulmonary vessels were counted and statistically compared.Design.— Fifty-four biopsies (27 cryobiopsies) from 18 patients (11 men) were reviewed. A median of 3 (range, 2–5) and 10 (range, 6–12) specimens were obtained with cryobiopsies and conventional biopsies, respectively. Cryobiopsies were larger and contained more alveoli (P < .001, both) and small airways (P = .04). Conventional biopsies showed more fresh alveolar hemorrhage (procedural) and crush artifact/atelectasis (P < .001, both). Cryobiopsies contained more pulmonary veins and venules (P < .001). There was no significant difference between the types of biopsies with respect to the reviewers' agreement on grades of rejection. Complications were more frequent in the cryobiopsy group, though the difference was not statistically significant.Results.— Cryobiopsies of lung allografts are larger and have less artifact. However, complications occur and should be considered. Three cryobiopsy specimens appear sufficient for histopathologic evaluation of lung allografts.Conclusions.—
Defining the Role of Dexmedetomidine in the Prevention of Delirium in the Intensive Care Unit
Nelson, Sarah , Muzyk, Andrew J. , Bucklin, Mason H., Brudney, Scott, Gagliardi, Jane P.

Mayo Clinic

BioMed Research International | October 19, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-7

10.1155/2015/635737 | PMID 26576429 Get It

Dexmedetomidine is a highly selectiveα2agonist used as a sedative agent. It also provides anxiolysis and sympatholysis without significant respiratory compromise or delirium. We conducted a systematic review to examine whether sedation of patients in the intensive care unit (ICU) with dexmedetomidine was associated with a lower incidence of delirium as compared to other nondexmedetomidine sedation strategies. A search of PUBMED, EMBASE, and the Cochrane Database of Systematic Reviews yielded only three trials from 1966 through April 2015 that met our predefined inclusion criteria and assessed dexmedetomidine and outcomes of delirium as their primary endpoint. The studies varied in regard to population, comparator sedation regimen, delirium outcome measure, and dexmedetomidine dosing. All trials are limited by design issues that limit our ability definitively to conclude that dexmedetomidine prevents delirium. Evidence does suggest that dexmedetomidine may allow for avoidance of deep sedation and use of benzodiazepines, factors both observed to increase the risk for developing delirium. Our assessment of currently published literature highlights the need for ongoing research to better delineate the role of dexmedetomidine for delirium prevention.
Improving Spiritual Well-Being in Patients with Lung Cancers
Piderman, Katherine M. , Sytsma, Terin T. , Frost, Marlene H., Novotny, Paul J. , Osian, Sarah M. Rausch, Sloan, Jeff A. , Rummans, Teresa A. , Bronars, Carrie, Clark, Matthew M. , Patten, Christi A. , Bronars, Carrie A, Nes, Lise Solberg , Yang, Ping

Mayo Clinic

Journal of Pastoral Care & Counseling: Advancing theory and professional practice through scholarly and reflective publicati | October 13, 2015 | Volume: 69 | Issue: 3 | Pages: 156-162

10.1177/1542305015602711 | PMID 26463853 Get It

Patients with lung cancer report more disease burden and lower spiritual well-being (SWB) compared with other cancer patients. Understanding variables that lessen disease burden and improve SWB is essential. The aim of this study was to explore the relationship between motivational level for physical activity and SWB in patients with lung cancer. Linear regression showed increased SWB as stage of change for physical activity increased (p < 0.0001), even after adjusting for multiple demographic variables.
Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Hurley, Paula J. , Sundi, Debasish , Shinder, Brian , Hughes, Robert M. , Miller, Rebecca M., Benzon, Benjamin , Faraj, Sheila F., Netto, George J. , Vergara, Ismael A. , Erho, Nicholas , Karnes, R. Jeffrey , Yan, Guifang, Ewing, Charles M., Isaacs, Sarah D., Berman, David M. , Rider, Jennifer R. , Jordahl, Kristina M. , Mucci, Lorelei A. , Huang, Jessie , An, Steven S. , Isaacs, William B. , Marchionni, Luigi , Ross, Ashley E. , Schaeffer, Edward M. , Simons, Brian W. , Davicioni, Elai , Park, Ben Ho

Mayo Clinic

Clinical Cancer Research | October 7, 2015 | Volume: 22 | Issue: 2 | Pages: 448-458

10.1158/1078-0432.ccr-15-0256 | PMID 26446945 Get It

Abstract Purpose: Prostate cancers incite tremendous morbidity upon metastatic growth. We previously identified Asporin (ASPN) as a potential mediator of metastatic progression found within the tumor microenvironment. ASPN contains an aspartic acid (D)-repeat domain and germline polymorphisms in D-repeat-length have been associated with degenerative diseases. Associations of germline ASPN D polymorphisms with risk of prostate cancer progression to metastatic disease have not been assessed. Experimental Design: Germline ASPN D-repeat-length was retrospectively analyzed in 1,600 men who underwent radical prostatectomy for clinically localized prostate cancer and in 548 noncancer controls. Multivariable Cox proportional hazards models were used to test the associations of ASPN variations with risk of subsequent oncologic outcomes, including metastasis. Orthotopic xenografts were used to establish allele- and stroma-specific roles for ASPN D variants in metastatic prostate cancer. Results: Variation at the ASPN D locus was differentially associated with poorer oncologic outcomes. ASPN D14 [HR, 1.72; 95% confidence interval (CI), 1.05–2.81, P = 0.032] and heterozygosity for ASPN D13/14 (HR, 1.86; 95% CI, 1.03–3.35, P = 0.040) were significantly associated with metastatic recurrence, while homozygosity for the ASPN D13 variant was significantly associated with a reduced risk of metastatic recurrence (HR, 0.44; 95% CI, 0.21–0.94, P = 0.035) in multivariable analyses. Orthotopic xenografts established biologic roles for ASPN D14 and ASPN D13 variants in metastatic prostate cancer progression that were consistent with patient-based data. Conclusions: We observed associations between ASPN D variants and oncologic outcomes, including metastasis. Our data suggest that ASPN expressed in the tumor microenvironment is a heritable modulator of metastatic progression. Clin Cancer Res; 22(2); 448–58. ©2015 AACR.
Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer
Kovtun, Irina V. , Johnson, Sarah H. , Cheville, John C. , Vasmatzis, George , Murphy, Stephen J.

Mayo Clinic

Oncotarget | September 29, 2015 | Volume: 6 | Issue: 30 | Pages: 29087-29096

10.18632/oncotarget.4900 | PMID 26337081 Get It

Sexual health in hematopoietic stem cell transplant recipients
Li, Zhuoyan , Mewawalla, Prerna , Yong, Agnes S. M. , Shaw, Bronwen E. , Hashmi, Shahrukh K. , Jagasia, Madan , Mohty, Mohamad , Majhail, Navneet S. , Hashmi, Shahrukh, Stratton, Pamela , Savani, Bipin N. , Rovó, Alicia , Majhail, Navneet S , Mohty, Mohamad

Mayo Clinic

Cancer | September 15, 2015 | Volume: 121 | Issue: 23 | Pages: 4124-4131

10.1002/cncr.29675 | PMID 26372459 Get It

Hematopoietic stem cell transplantation (HSCT) plays a central role in patients with malignant and, increasingly, nonmalignant conditions. As the number of transplants increases and the survival rate improves, long‐term complications are important to recognize and treat to maintain quality of life. Sexual dysfunction is a commonly described but relatively often underestimated complication after HSCT. Conditioning regimens, generalized or genital graft‐versus‐host disease, medications, and cardiovascular complications as well as psychosocial problems are known to contribute significantly to physical and psychological sexual dysfunction. Moreover, it is often a difficult topic for patients, their significant others, and health care providers to discuss. Early recognition and management of sexual dysfunction after HSCT can lead to improved quality of life and outcomes for patients and their partners. This review focuses on the risk factors for and treatment of sexual dysfunction after transplantation and provides guidance concerning how to approach and manage a patient with sexual dysfunction after HSCT. Cancer 2015;121:4124–4131. © 2015 American Cancer Society.
2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative
Dejaco, Christian , Singh, Yogesh Preet , Perel, Pablo , Hutchings, Andrew , Camellino, Dario , Mackie, Sarah , Abril, Andy , Bachta, Artur , Bálint, Péter, Barraclough, Kevin, Bianconi, L., Buttgereit, Frank , Carsons, Steven E. , Ching, Daniel , Cid, María C. , Cimmino, Marco A. , Diamantopoulos, Andreas P. , Docken, William P., Duftner, Christina , Fashanu, Billy, Gilbert, Kate, Hildreth, Pamela, Hollywood, Jane, Jayne, David , Lima, Manuella , Maharaj, Ajesh B. , Mallen, Christian , Martínez‐Taboada, Víctor M. , Maz, Mehrdad , Merry, Steven, Miller, Jean , Mori, Shunsuke , Nordborg, Elisabeth, Nott, Jennifer, Padbury, Hannah, Pease, Colin, Salvarani, Carlo , Schirmer, Michael , Schmidt, Wolfgang , Tronnier, David, Wagner, Alexandre, Whitlock, Madeline, Matteson, Eric L. , Merry, Stephen , Souza, Alexandre Wagner Silva de , Neill, Lorna M. , Salvarani, Carlo , Spiera, Robert , Wagner, Alexandre, Dasgupta, Bhaskar , Dejaco, Christian , Merry, Stephen P , Mackie, Sarah Louise , Jayne, David , Buttgereit, Frank , Singh, Yogesh Preet , de Souza, Alexandre Wagner Silva

Mayo Clinic

Arthritis & Rheumatology | September 10, 2015 | Volume: 67 | Issue: 10 | Pages: 2569-2580

10.1002/art.39333 | PMID 26352874 Get It

Abstract Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients’ and clinicians’ values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow‐up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying anti‐rheumatic drugs (DMARDs), as well as the roles of non‐steroidal anti‐rheumatic drugs and non‐pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR.